430 related articles for article (PubMed ID: 21138720)
21. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
[TBL] [Abstract][Full Text] [Related]
22. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
DeSantis SM; Bandyopadhyay D; Baker NL; Randall PK; Anton RF; Prisciandaro JJ
Drug Alcohol Depend; 2013 Sep; 132(1-2):244-50. PubMed ID: 23566774
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Kranzler HR; Van Kirk J
Alcohol Clin Exp Res; 2001 Sep; 25(9):1335-41. PubMed ID: 11584154
[TBL] [Abstract][Full Text] [Related]
24. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Namkoong K; Lee BO; Lee PG; Choi MJ; Lee E
Alcohol Alcohol; 2003; 38(2):135-41. PubMed ID: 12634260
[TBL] [Abstract][Full Text] [Related]
25. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
26. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Alcohol; 2012 Mar; 46(2):121-31. PubMed ID: 21925828
[TBL] [Abstract][Full Text] [Related]
27. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
[TBL] [Abstract][Full Text] [Related]
28. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Weiss RD; O'malley SS; Hosking JD; Locastro JS; Swift R;
J Stud Alcohol Drugs; 2008 Nov; 69(6):878-84. PubMed ID: 18925346
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
[TBL] [Abstract][Full Text] [Related]
30. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Mason BJ
J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
[TBL] [Abstract][Full Text] [Related]
31. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Soyka M; Rösner S
Curr Drug Abuse Rev; 2008 Nov; 1(3):280-91. PubMed ID: 19630726
[TBL] [Abstract][Full Text] [Related]
32. [The pharmacologic treatment of the alcohol dependence].
Castro LA; Baltieri DA
Braz J Psychiatry; 2004 May; 26 Suppl 1():S43-6. PubMed ID: 15729444
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Snyder JL; Bowers TG
Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
[TBL] [Abstract][Full Text] [Related]
34. Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Witkiewitz K; Bowen S; Donovan DM
J Consult Clin Psychol; 2011 Feb; 79(1):54-63. PubMed ID: 21261434
[TBL] [Abstract][Full Text] [Related]
35. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
Gueorguieva R; Wu R; Krystal JH; Donovan D; O'Malley SS
Addict Behav; 2013 May; 38(5):2119-27. PubMed ID: 23435273
[TBL] [Abstract][Full Text] [Related]
36. Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Klemperer EM; Hughes JR; Naud S
Drug Alcohol Depend; 2018 Sep; 190():229-234. PubMed ID: 30059816
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Maisel NC; Blodgett JC; Wilbourne PL; Humphreys K; Finney JW
Addiction; 2013 Feb; 108(2):275-93. PubMed ID: 23075288
[TBL] [Abstract][Full Text] [Related]
38. Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
Worley MJ; Witkiewitz K; Brown SA; Kivlahan DR; Longabaugh R
Alcohol Clin Exp Res; 2015 Jan; 39(1):93-100. PubMed ID: 25623409
[TBL] [Abstract][Full Text] [Related]
39. [Acamprosate and naltrexone: similar efficacy for relapse].
Saitz R
Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
[No Abstract] [Full Text] [Related]
40. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Drug Alcohol Depend; 2010 Mar; 107(2-3):221-9. PubMed ID: 19969427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
